Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart versus IVIg in Chronic Inflammatory Demyelinating Polyneuropathy
NCT06920004Phase 3Recruiting
- Sponsor
- argenx
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by argenx. Primary endpoint: adjusted Inflammatory Neuropathy Cause and Treatment score reduction ≥1 point at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06920004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920004.